M.D., Ph.D., VP Scientific & Medical Affairs, Molecular Health GmbH
Dr Armin Schneider has 20 years track record in leading roles in Biotech drug discovery and development and MD PhD from the University of Heidelberg, Germany. At Molecular Health, Armin pioneers the utilization of the company’s technology, Dataome® – a mighty clinical-molecular knowledge base of drugs, diseases and outcomes into machine learning applications and predictive algorithms to predict drug outcomes and R&D efficiency. He has authored over 150 publications and owns numerous patent families and has a strong background in neurology, pharmacology, molecular biology, and statistics, and specific interest in questions of applying advanced statistical methodology to drug development.
Session Abstract – PMWC 2019 Silicon Valley
Session Synopsis: Imaging plays pivotal roles in the diagnosis, pathology staging, treatment response assessment, and the prognosis of many cancers. It is a crucial part of precision patient care and advancing at a rapid pace with innovative developments in imaging sciences, algorithm development, and an improved understanding of the complex biology of cancer. This session focus of how precision imaging may assist with optimal clinical decision-making and outcomes prediction.